BI-RADS 3 Assessment on MRI: A Lesion-Based Review for Breast Radiologists

Derek L. Nguyen; Kelly Myers; Eniola Oluyemi; Lisa A. Mullen; Babita Panigrahi; Joanna Rossi; Emily B. Ambinder

doi:10.1093/jbi/wbac032

BI-RADS 3 Assessment on MRI: A Lesion-Based Review for Breast Radiologists

Derek L. Nguyen, Kelly Myers, Eniola Oluyemi, Lisa A. Mullen, Babita Panigrahi, Joanna Rossi, Emily B. Ambinder

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Unlike mammography and US, limited data exist to establish well-defined criteria for MRI findings that have a ≤2% likelihood of malignancy. Therefore, determining which findings are appropriate for a BI-RADS 3 assessment on MRI remains challenging and variable among breast radiologists. Emerging data suggest that BI-RADS 3 should be limited to baseline MRI examinations (or examinations with less than two years of prior comparisons) performed for high-risk screening and only used for masses with all of the typical morphological and kinetic features suggestive of a fibroadenoma or dominant enhancing T2 hypointense foci that is distinct from background parenchymal enhancement and without suspicious kinetics. This article presents an updated discussion of BI-RADS 3 assessment (probably benign) for breast MRI using current evidence.

Original language	English (US)
Pages (from-to)	460-473
Number of pages	14
Journal	Journal of Breast Imaging
Volume	4
Issue number	5
DOIs	https://doi.org/10.1093/jbi/wbac032
State	Published - Sep 1 2022

Keywords

BI-RADS 3
breast MRI
probably benign

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Radiology Nuclear Medicine and imaging

Access to Document

10.1093/jbi/wbac032

Cite this

@article{f5361c3d869340cd90b1d79343be50aa,

title = "BI-RADS 3 Assessment on MRI: A Lesion-Based Review for Breast Radiologists",

abstract = "Unlike mammography and US, limited data exist to establish well-defined criteria for MRI findings that have a ≤2% likelihood of malignancy. Therefore, determining which findings are appropriate for a BI-RADS 3 assessment on MRI remains challenging and variable among breast radiologists. Emerging data suggest that BI-RADS 3 should be limited to baseline MRI examinations (or examinations with less than two years of prior comparisons) performed for high-risk screening and only used for masses with all of the typical morphological and kinetic features suggestive of a fibroadenoma or dominant enhancing T2 hypointense foci that is distinct from background parenchymal enhancement and without suspicious kinetics. This article presents an updated discussion of BI-RADS 3 assessment (probably benign) for breast MRI using current evidence.",

keywords = "BI-RADS 3, breast MRI, probably benign",

author = "Nguyen, {Derek L.} and Kelly Myers and Eniola Oluyemi and Mullen, {Lisa A.} and Babita Panigrahi and Joanna Rossi and Ambinder, {Emily B.}",

note = "Funding Information: K.S.M. receives grant funding from the National Institutes of Health for an activity not related to the topic of this article. E.O. receives grant funding from GE Healthcare, as a recipient of the AUR GERRAF award, for an activity not related to the topic of this article. E.B.A. receives grant funding from The Nexus Fund and an RSNA Research Scholar Grant for activities not related to the topic of this article. Publisher Copyright: {\textcopyright} Society of Breast Imaging 2022. All rights reserved.",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/jbi/wbac032",

language = "English (US)",

volume = "4",

pages = "460--473",

journal = "Journal of Breast Imaging",

issn = "2631-6110",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - BI-RADS 3 Assessment on MRI

T2 - A Lesion-Based Review for Breast Radiologists

AU - Nguyen, Derek L.

AU - Myers, Kelly

AU - Oluyemi, Eniola

AU - Mullen, Lisa A.

AU - Panigrahi, Babita

AU - Rossi, Joanna

AU - Ambinder, Emily B.

N1 - Funding Information: K.S.M. receives grant funding from the National Institutes of Health for an activity not related to the topic of this article. E.O. receives grant funding from GE Healthcare, as a recipient of the AUR GERRAF award, for an activity not related to the topic of this article. E.B.A. receives grant funding from The Nexus Fund and an RSNA Research Scholar Grant for activities not related to the topic of this article. Publisher Copyright: © Society of Breast Imaging 2022. All rights reserved.

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Unlike mammography and US, limited data exist to establish well-defined criteria for MRI findings that have a ≤2% likelihood of malignancy. Therefore, determining which findings are appropriate for a BI-RADS 3 assessment on MRI remains challenging and variable among breast radiologists. Emerging data suggest that BI-RADS 3 should be limited to baseline MRI examinations (or examinations with less than two years of prior comparisons) performed for high-risk screening and only used for masses with all of the typical morphological and kinetic features suggestive of a fibroadenoma or dominant enhancing T2 hypointense foci that is distinct from background parenchymal enhancement and without suspicious kinetics. This article presents an updated discussion of BI-RADS 3 assessment (probably benign) for breast MRI using current evidence.

AB - Unlike mammography and US, limited data exist to establish well-defined criteria for MRI findings that have a ≤2% likelihood of malignancy. Therefore, determining which findings are appropriate for a BI-RADS 3 assessment on MRI remains challenging and variable among breast radiologists. Emerging data suggest that BI-RADS 3 should be limited to baseline MRI examinations (or examinations with less than two years of prior comparisons) performed for high-risk screening and only used for masses with all of the typical morphological and kinetic features suggestive of a fibroadenoma or dominant enhancing T2 hypointense foci that is distinct from background parenchymal enhancement and without suspicious kinetics. This article presents an updated discussion of BI-RADS 3 assessment (probably benign) for breast MRI using current evidence.

KW - BI-RADS 3

KW - breast MRI

KW - probably benign

UR - http://www.scopus.com/inward/record.url?scp=85136369317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136369317&partnerID=8YFLogxK

U2 - 10.1093/jbi/wbac032

DO - 10.1093/jbi/wbac032

M3 - Review article

C2 - 36247094

AN - SCOPUS:85136369317

SN - 2631-6110

VL - 4

SP - 460

EP - 473

JO - Journal of Breast Imaging

JF - Journal of Breast Imaging

IS - 5

ER -

BI-RADS 3 Assessment on MRI: A Lesion-Based Review for Breast Radiologists

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this